Amyloid-beta (1-40) and Mortality in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome A Cohort Study

作者：Stamatelopoulos Kimon; Mueller Hennessen Matthias; Georgiopoulos Georgios; Sachse Marco; Boeddinghaus Jasper; Sopova Kateryna; Gatsiou Aikaterini; Amrhein Carolin; Biener Moritz; Vafaie Mehrshad; Athanasouli Fani; Stakos Dimitrios; Pateras Konstantinos; Twerenbold Raphael; Badertscher Patrick; Nestelberger Thomas; Dimmeler Stefanie; Katus Hugo A; Zeiher Andreas M; Mueller Christian; Giannitsis Evangelos; Stellos Konstantinos

来源：Annals of Internal Medicine, 2018, 168(12): 855-+.

DOI：10.7326/M17-1540

Background: Amyloid-beta (1-40) (A beta 40) is implicated in mechanisms related to plaque destabilization and correlates with adverse outcomes in stable coronary artery disease.
Objective: To determine the prognostic and reclassification value of baseline circulating levels of A beta 40 after adjustment for the Global Registry of Acute Coronary Events (GRACE) score, which is widely recommended for risk stratification in non-ST segment elevation acute coronary syndrome (NSTE-ACS).
Design: Retrospective cohort study using data from 2 independent prospective cohorts, the Heidelberg study (n = 1145) and the validation multicenter international APACE (Advantageous Predictors of Acute Coronary Syndrome Evaluation) study (n = 734).
Setting: Academic hospitals in 7 European countries.
Participants: Patients with adjudicated NSTE-ACS followed for a median of 21.9 and 24.9 months in the Heidelberg and APACE studies, respectively.
Measurements: All-cause mortality was the primary end point.
Results: Amyloid-beta (1-40) was associated with mortality after multivariate adjustment for age, sex, diabetes mellitus, high-sensitivity cardiac troponin T and C-reactive protein, revascularization, and ACS type (Heidelberg cohort hazard ratio [HR] for 80th vs. 20th percentiles, 1.66 [95% CI, 1.06 to 2.61; P = 0.026]; APACE cohort HR, 1.50 [CI, 1.15 to 1.96; P = 0.003]). It was also associated with mortality after adjustment for the GRACE score (Heidelberg cohort HR for 80th vs. 20th percentiles, 1.11 [CI, 1.04 to 1.18; P = 0.001]; APACE cohort HR, 1.39 [CI, 1.02 to 1.88; P = 0.036]). Amyloid-beta (1-40) correctly reclassified risk for death over the GRACE score (net reclassification index, 33.4% and 47.1% for the Heidelberg and APACE cohorts, respectively) (P < 0.05).
Limitation: At low concentrations of A beta 40, dose-response associations with mortality differed between cohorts, possibly because of varying blood preparations used to measure A beta 40.
Conclusion: Circulating A beta 40 is a predictor of mortality and improves risk stratification of patients with NSTE-ACS over the GRACE score recommended by clinical guidelines. The clinical application of A beta 40 as a novel biomarker in NSTE-ACS should be further explored and validated.

• 出版日期2018-6-19